Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/70081
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants' allergies in first year of life: randomised controlled trial |
Author: | Palmer, D. Sullivan, T. Gold, M. Prescott, S. Heddle, R. Gibson, R. Makrides, M. |
Citation: | BMJ: British Medical Journal, 2012; 344(7845):E184-1-E184-11 |
Publisher: | British Med Journal Publ Group |
Issue Date: | 2012 |
ISSN: | 0959-535X 1756-1833 |
Statement of Responsibility: | D J Palmer, T Sullivan, M S Gold, S L Prescott, R Heddle, R A Gibson, M Makrides |
Abstract: | Objective: To determine whether dietary n-3 long chain polyunsaturated fatty acid (LCPUFA) supplementation of pregnant women with a fetus at high risk of allergic disease reduces immunoglobulin E associated eczema or food allergy at 1 year of age. Design: Follow-up of infants at high hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome (DOMInO) randomised controlled trial. Setting: Adelaide, South Australia. Participants: 706 infants at high hereditary risk of developing allergic disease whose mothers were participating in the DOMInO trial. Interventions: The intervention group (n=368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks’ gestation until birth; the control group (n=338) received matched vegetable oil capsules without n-3 LCPUFA. Main outcome measure: Immunoglobulin E associated allergic disease (eczema or food allergy with sensitisation) at 1 year of age. Results: No differences were seen in the overall percentage of infants with immunoglobulin E associated allergic disease between the n-3 LCPUFA and control groups (32/368 (9%) v 43/338 (13%); unadjusted relative risk 0.68, 95% confidence interval 0.43 to 1.05, P=0.08; adjusted relative risk 0.70, 0.45 to 1.09, P=0.12), although the percentage of infants diagnosed as having atopic eczema (that is, eczema with associated sensitisation) was lower in the n-3 LCPUFA group (26/368 (7%) v 39/338 (12%); unadjusted relative risk 0.61, 0.38 to 0.98, P=0.04; adjusted relative risk 0.64, 0.40 to 1.02, P=0.06). Fewer infants were sensitised to egg in the n-3 LCPUFA group (34/368 (9%) v 52/338 (15%); unadjusted relative risk 0.61, 0.40 to 0.91, P=0.02; adjusted relative risk 0.62, 0.41 to 0.93, P=0.02), but no difference between groups in immunoglobulin E associated food allergy was seen. Conclusion: n-3 LCPUFA supplementation in pregnancy did not reduce the overall incidence of immunoglobulin E associated allergies in the first year of life, although atopic eczema and egg sensitisation were lower. Longer term follow-up is needed to determine if supplementation has an effect on respiratory allergic diseases and aeroallergen sensitisation in childhood. |
Keywords: | Fetal Blood Humans Dermatitis, Atopic Hypersensitivity, Immediate Food Hypersensitivity Fatty Acids, Omega-3 Fish Oils Immunoglobulin E Treatment Outcome Regression Analysis Breast Feeding Pregnancy Infant Formula Dietary Supplements Eggs Infant Australia Female Male Maternal Nutritional Physiological Phenomena Intention to Treat Analysis Confounding Factors, Epidemiologic |
Rights: | © The Authors |
DOI: | 10.1136/bmj.e184 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/399389 |
Published version: | http://dx.doi.org/10.1136/bmj.e184 |
Appears in Collections: | Aurora harvest 5 Paediatrics publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_70081.pdf | Published version | 368.92 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.